Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT05359432
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT05359432
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Pakistan
- Registry status
- Completed
Technical summary
Registry record NCT05359432. Randomized; no masking; primary purpose treatment. Start 2020-07-01 (actual); primary completion 2021-08-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Vildagliptin
- Lead sponsor
- Getz Pharma
Record details
- Record id
cardio:ct-nct05359432- Content hash
91874293e830f8c409577403e9c64bda904d885bd2ac10381a78c23cb581803f